(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
1.83% $ 2.23
Live Chart Being Loaded With Signals
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use...
Stats | |
---|---|
Объем за сегодня | 4.48M |
Средний объем | 599 679 |
Рыночная капитализация | 127.83M |
EPS | $0 ( 2024-03-14 ) |
Дата следующего отчета о доходах | ( $0 ) 2024-05-07 |
Last Dividend | $0.667 ( 2014-10-31 ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.01 |
ATR14 | $0.0250 (1.12%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-09-21 | Baylor-henry Minnie | Sell | 32 800 | Common Stock |
2023-09-21 | Baylor-henry Minnie | Sell | 26 400 | Common Stock |
2023-09-21 | Baylor-henry Minnie | Sell | 12 800 | Stock option (right to buy) |
2023-09-21 | Hoffmann Rolf K | Sell | 64 000 | Common Stock |
2023-09-21 | Hoffmann Rolf K | Sell | 20 000 | Common Stock |
INSIDER POWER |
---|
-64.25 |
Last 96 transactions |
Buy: 1 606 755 | Sell: 5 363 965 |
Объем Корреляция
Paratek Pharmaceuticals Корреляция
10 Самые положительные корреляции | |
---|---|
PAIC | 0.948 |
SVOK | 0.947 |
BIOL | 0.912 |
RMRM | 0.909 |
YMAB | 0.899 |
SVAC | 0.89 |
AVCT | 0.883 |
TSP | 0.879 |
UK | 0.876 |
GAINL | 0.876 |
10 Самые отрицательные корреляции | |
---|---|
BOCH | -0.954 |
NETE | -0.938 |
MMAC | -0.912 |
RAVN | -0.903 |
SHSP | -0.9 |
LMRK | -0.894 |
QADA | -0.878 |
VLYPO | -0.862 |
AMRB | -0.862 |
PODD | -0.858 |
Вы знали?
Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).
Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.
Paratek Pharmaceuticals Корреляция - Валюта/Сырье
Paratek Pharmaceuticals Финансовые показатели
Annual | 2022 |
Выручка: | $150.79M |
Валовая прибыль: | $127.73M (84.71 %) |
EPS: | $-1.170 |
FY | 2022 |
Выручка: | $150.79M |
Валовая прибыль: | $127.73M (84.71 %) |
EPS: | $-1.170 |
FY | 2021 |
Выручка: | $130.16M |
Валовая прибыль: | $108.63M (83.46 %) |
EPS: | $-1.201 |
FY | 2020 |
Выручка: | $46.92M |
Валовая прибыль: | $38.27M (81.56 %) |
EPS: | $-2.19 |
Financial Reports:
No articles found.
Paratek Pharmaceuticals Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $15.96 | 2014-05-21 |
Last Dividend | $0.667 | 2014-10-31 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 4 | -- |
Total Paid Out | $40.59 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.91 | -- |
Div. Sustainability Score | 0.312 | |
Div.Growth Potential Score | 0.170 | |
Div. Directional Score | 0.241 | -- |
Year | Amount | Yield |
---|---|---|
2014 | $40.59 | 172.60% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.299 | 1.500 | -5.98 | -8.98 | [0 - 0.5] |
returnOnAssetsTTM | -0.287 | 1.200 | -9.57 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.224 | 1.500 | 8.63 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 0.519 | 0.800 | -2.40 | -1.923 | [1 - 3] |
quickRatioTTM | 0.420 | 0.800 | -2.23 | -1.786 | [0.8 - 2.5] |
cashRatioTTM | 0.211 | 1.500 | 9.94 | 10.00 | [0.2 - 2] |
debtRatioTTM | 1.782 | -1.500 | 10.00 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -1.959 | 1.000 | -1.837 | -1.837 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.189 | 2.00 | -0.0628 | -0.126 | [0 - 30] |
freeCashFlowPerShareTTM | -0.190 | 2.00 | -0.0949 | -0.190 | [0 - 20] |
debtEquityRatioTTM | -1.290 | -1.500 | -5.16 | 7.74 | [0 - 2.5] |
grossProfitMarginTTM | 0.850 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.201 | 1.000 | -6.01 | -6.01 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -0.0416 | 1.000 | -1.342 | -1.342 | [0.2 - 2] |
assetTurnoverTTM | 0.960 | 0.800 | 6.94 | 5.55 | [0.5 - 2] |
Total Score | 0.312 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -3.05 | 1.000 | -0.409 | 0 | [1 - 100] |
returnOnEquityTTM | 0.224 | 2.50 | 9.12 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.190 | 2.00 | -0.0632 | -0.190 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.189 | 2.00 | -0.0628 | -0.126 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.179 | 1.500 | -2.14 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -0.0772 | 1.000 | -4.43 | 0 | [0.1 - 0.5] |
Total Score | 0.170 |
Paratek Pharmaceuticals
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. In addition, it has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.
О Торговые сигналы
Данные торговые сигналы, представленные на этой странице, помогают определить, когда следует ПОКУПАТЬ или ПРОДАВАТЬ NA. Сигналы имеют задержку более 1 минуты. Пожалуйста, примите во внимание, что существует вероятность ошибки или неточностей в силу различных микро и макро факторов влияющих на фондовые рынки.
Данные тор“о”ые сигна“ы не являются определен“ыми, и getagraph.com не несет ответственности за какие-либо действия, предпринятые в от“ошении этих сигналов, как описано в Terms of Use. Сигналы основаны на широком спектре индикаторов технического анализа